Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $3.75 in the prior trading day, AVITA Medical Inc (NASDAQ: RCEL) closed at $3.91, up 4.27%. In other words, the price has increased by $4.27 from its previous closing price. On the day, 0.16 million shares were traded. RCEL stock price reached its highest trading level at $3.925 during the session, while it also had its lowest trading level at $3.75.
Ratios:
Our goal is to gain a better understanding of RCEL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 0.67.
On August 08, 2025, BTIG Research Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $3.
On December 24, 2024, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $25.D. Boral Capital initiated its Buy rating on December 24, 2024, with a $25 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 28 ’25 when McNamara Robert bought 10,000 shares for $4.50 per share. The transaction valued at 45,000 led to the insider holds 86,771 shares of the business.
O’Toole David D bought 2,000 shares of RCEL for $9,040 on Aug 26 ’25. The CFO now owns 31,657 shares after completing the transaction at $4.52 per share. On Aug 19 ’25, another insider, McNamara Robert, who serves as the Director of the company, bought 10,000 shares for $5.00 each. As a result, the insider paid 50,000 and bolstered with 76,771 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCEL now has a Market Capitalization of 119228072 and an Enterprise Value of 140688064. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.34. Its current Enterprise Value per Revenue stands at 1.943 whereas that against EBITDA is -3.515.
Stock Price History:
The Beta on a monthly basis for RCEL is 1.65, which has changed by -0.7074883 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, RCEL has reached a high of $14.16, while it has fallen to a 52-week low of $3.35. The 50-Day Moving Average of the stock is -12.76%, while the 200-Day Moving Average is calculated to be -37.95%.
Shares Statistics:
The stock has traded on average 564.47K shares per day over the past 3-months and 220360 shares per day over the last 10 days, according to various share statistics. A total of 30.49M shares are outstanding, with a floating share count of 24.52M. Insiders hold about 1.30% of the company’s shares, while institutions hold 20.78% stake in the company. Shares short for RCEL as of 1763078400 were 3017151 with a Short Ratio of 5.35, compared to 1760486400 on 3164050. Therefore, it implies a Short% of Shares Outstanding of 3017151 and a Short% of Float of 9.959999999999999.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.37 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$2.46 and -$2.78 for the fiscal current year, implying an average EPS of -$2.63. EPS for the following year is -$1.42, with 6.0 analysts recommending between -$0.35 and -$2.37.
Revenue Estimates
6 analysts predict $26.86M in revenue for. The current quarter. It ranges from a high estimate of $29.08M to a low estimate of $24.75M. As of. The current estimate, AVITA Medical Inc’s year-ago sales were $29.21MFor the next quarter, 6 analysts are estimating revenue of $30.03M. There is a high estimate of $31.68M for the next quarter, whereas the lowest estimate is $27.07M.
A total of 10 analysts have provided revenue estimates for RCEL’s current fiscal year. The highest revenue estimate was $112.63M, while the lowest revenue estimate was $107.31M, resulting in an average revenue estimate of $110.05M. In the same quarter a year ago, actual revenue was $101.97MBased on 10 analysts’ estimates, the company’s revenue will be $143.8M in the next fiscal year. The high estimate is $183.23M and the low estimate is $120.66M.
